Zobrazeno 1 - 10
of 115
pro vyhledávání: '"J G, Copeland"'
Publikováno v:
Surgical technology international. 2
The total artificial heart (TAH) is a device that fully replaces the failing heart and provides control of the circulatory system. This device has been used to provide permanent support, however, its most important role is to serve as a bridge to car
Publikováno v:
Diabetes. 46:1859-1867
Publikováno v:
Circulation Research. 72:440-454
We determined the influences of breathing-induced changes in intrathoracic and intravascular pressures, central respiratory drive, and pulmonary vagal feedback on the within-breath variation in skeletal muscle sympathetic nerve activity (MSNA) in hum
Autor:
J G, Copeland, M, McCarthy
Publikováno v:
Clinical transplants.
Among 391 patients who received heart transplants at the University of Arizona since 1990, the percentage of bridge-to-transplant device patients receiving donor hearts has increased from 6.7% to 50%. Survival after transplantation in this-bridge-to
Publikováno v:
The journal of extra-corporeal technology. 31(4)
Potential thoracic organ transplantation recipients who have positive cytotoxic antibody screens as quantified panel reactive antibodies (PRA) are at risk for immediate or long-term immunologic events that may affect the donor organ. The patient popu
Autor:
J G, Copeland
Publikováno v:
Artificial organs. 22(11)
The total artificial heart (TAH) now known as the Cardio West was the product of work in Dr. Willem Kolff's laboratory at the University of Utah. It made a clinical debut in the early 1980s as a permanent device, the Jarvik-7 TAH. In the mid 1980s, i
Autor:
F A, Arabia, J G, Copeland, R G, Smith, G K, Sethi, D A, Arzouman, A, Pavie, D, Duveau, W J, Keon, R, Masters, B, Foy, M, Carrier, W, Dembitsky, J, Long, R, Kormos
Publikováno v:
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
As the number of potential heart donors remains constant and the number of potential recipients continuous to increase, the need for circulatory devices to bridge patients becomes more important. The CardioWest total artificial heart (TAH) is a pneum
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 15(9)
Advances in myocardial preservation techniques and immunosuppressive drug therapy have resulted in heart transplantation as an acceptable treatment for end-stage heart failure. However, excessive periods of global myocardial ischemia followed by repe
Autor:
J G, Copeland
Publikováno v:
Seminars in thoracic and cardiovascular surgery. 8(3)
The CarboMedics prosthetic heart valve has been studied in more than 2,933 patients for a total of 6,298-patient years, with mean follow-up periods of as long as 36 months in patient populations typical for the standard practice of cardiac surgery. S
Autor:
J G, Copeland, A, Pavie, D, Duveau, W J, Keon, R, Masters, R, Pifarre, R G, Smith, F A, Arabia
Publikováno v:
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 15(1 Pt 1)
After reapproval by the Food and Drug Administration of the CardioWest total artificial heart for clinical investigation, an international study was started in January 1993 to ascertain the safety and efficacy of this device for bridging to heart tra